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without TDF add-on in the treatment of CHB. METHODS: Analysis population con-
sisted of patients (n1000; 35% HBeAg-positive; 35 years old) without compensated
or decompensated cirrhosis(CC, DC) or hepatocellular cancer(HCC). AVs compared
were 1) Ldt 600mg/day; 2) Ldt add-on TDF 300mg/day when non-response or viral
resistance occurs; and 3)LAM 100mg/day (4)LAM add-on TDF 300mg/day. A deci-
sion tree model with 5 parallel pathways for different levels of HBV-DNA was built
using a 10-year time-horizon. Selected major clinical outcomes were mortality and
life-years-lost (LYL). RESULTS: With LAM or Ldt monotherapy, 137CC, 5DC, 40 HCC
cases and 70 dead versus 85CC, 3,5DC and 25HCC cases and 44 dead were expected
to occur, respectively. With LAM or Ldt monotherapy, 1236 and 774 life-years will
be lost, respectively. When a potent AV is added to LAM or Ldt, HBV complications
were expected to decrease and avoided LYL were substantial (164 to 591 years,
respectively). However, there is no important difference between starting with
LAM or Ldt and adding TDF strategies: 1CC, 0 DC, 0HCC cases and 2 dead will be
avoided. CONCLUSIONS: Ldt monotherapy was found to be superior to LAM mono-
therapy. However, Ldt TDF does not seem a better approach than LAMTDF in
the treatment of CHB. This paradoxical finding might be explained due to margin-
ally superior efficacy of Ldt versus LAM and a longer time-period before adding a
potent antiviral to treatment.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global
epidemics with significant unmet need and disease burden. One of the major lim-
itations of current treatments is the need for 12 or 6 months of Interferon based
therapy, which has tolerability and toxicity issues for many patients. During last
2-3 years several new agents have been tested in clinic, which have shown prom-
ising results as non-interferon based therapy. Goal of this study was to review the
clinical efficacy and safety profile of non-interferon based therapies for HCV
treatment. METHODS: We searched the MEDLINE, and abstracts from AASLD and
EASL until May 2011. Studies were selected for clinical trials on direct acting agents
for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxic-
ity was evaluated as secondary endpoint. Aggregated data were further analyzed to
understand comparative safety and efficacy. RESULTS: Until May 2011, results of
five eligible HCV clinical trials for interferon free regimens were available. Overall,
treatment with combination of protease and polymerase inhibitor showed dra-
matic viral load reduction after 2 weeks of treatment. The combination of PSI-7977
and PSI-938 showed 93% viral clearance after 14 days (n16). The combination of
RG7227 and RG7128 demonstrated 5.1 log reduction in viral load in treatment naive,
and 4.9 log reduction in null responder patients after 14 days of treatment. The
combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null
responder patients. One study evaluating VX-222 and Telaprevir combination was
discontinued due to viral breakthrough. Several studies are currently on-going
whose data would be available in 2011-2012. CONCLUSIONS:Non-interferon based
therapies have shown impressive viral load reduction in short term studies. How-
ever, more data for SVR, viral breakthrough and resistance is needed to confirm
their safe use in HCV infected population.
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OBJECTIVES: To describe the clinical and economic burden associated with hospi-
tal onset health care facility acquired Clostridium difficile infection (HO-HCFA-CDI)
in European health care facilities (EHCF). METHODS: A systematic review of the
PubMed, EMBASE and infectious disease societies was performed to capture clini-
cal and economic burden of HO-HCFA-CDI in Europe. Included studies were pub-
lished in English between 2000-2010 and had 20 patients with documented CDI
acquired/treated in a EHCF. Data collection was completed by three un-blinded
reviewers using Cochrane Handbook and PRISMA guidelines. The primary out-
comes were mortality, recurrence, length of stay (LOS) and cost related to CDI.
RESULTS: We identified 1138 primary articles and conference abstracts, which
were narrowed to 38 and 30 studies, respectively, after applying eligibility criteria.
Outcomes data were available from only 14 countries, with 47% of studies from UK
institutions. CDI mortality at 30 days ranged from 2% in France to 42% in the UK.
Mortality rates more than doubled from 1999-2004, and continued to rise until 2007,
when reductions were noted in the UK. Recurrent CDI varied from 1% in France to
36% in Ireland; however, equivalent recurrence definitions were not used, which
affects study outcomes. Median length of stay ranged from 8 days in Belgium to 124
days in the UK. The incremental cost of CDI was £4,577 in Ireland and £11,317 in
Germany, after standardization to 2010 GBP. Country-specific averages, weighted
by study sample sizes, ranged from 2.8% to 29.8% for 30-day mortality; 5.9% to
22.6% for recurrence; and, 16.1 to 37.9 days for LOS. CONCLUSIONS: Burden of CDI
in Europe was most commonly described using 30-day mortality, recurrence, LOS
and cost data. Country-specific reporting mandates partly influence the available
data on CDI burden in EHCFs. The continued spread of CDI and resultant healthcare
burden underscores the need for judicious antibiotic use.
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OBJECTIVES: With adherence being a driver of treatment efficacy, we aimed to
systematically assess treatment adherence and efficacy in a disease area impacted
by the rapid emergence of multiple drug resistances as a result of non-adherence,
tuberculosis. We systematically reviewed the literature to qualitatively assess the
impact of directly observed therapy (DOT) versus other treatment modalities (non-
DOT) on adherence and treatment efficacy in patients with tuberculosis.
METHODS: English-language literature indexed in the MEDLINE database (ac-
cessed via PubMed) from January 1, 2000 through November 5, 2010 was systemat-
ically reviewed. Experimental and observational studies with at least 10 patients
and one treatment group receiving a DOT were included and reviewed for adher-
ence and efficacy outcomes. RESULTS: Thirty-seven tuberculosis studies were in-
cluded. Twelve studies reported outcomes for both DOTs and non-DOTs. Six com-
parative studies reported treatment completion; DOT was numerically favored in
5/6 studies, with 3 studies showing significant treatment completion rate benefit in
the DOT group. In Daneil et al., the DOT treatment completion benefit (61.6% DOT,
41.5% non-DOT) paralleled significantly less mortality (9.2% DOT, 19.8% non-DOT)
and greater treatment success (61.6% DOT, 41.5% non-DOT) (p0.001). In Chee et
al., significantly greater treatment completion (89.2% vs. 70.7%) and fewer treat-
ment interruptions (4.0% vs. 12.9%) in the DOT group paralleled fewer deaths (4.2%
vs. 13.1%; p0.001). Only one study showed lower treatment completion and more
deaths for the DOT. However these results were juxtaposed with a higher cure rate
and less treatment default. CONCLUSIONS: DOT has shown specific positive clin-
ical impact by reducing mortality, and increasing treatment success and cure rate
through increased adherence. This suggests the social pressure of health care pro-
fessional involvement in observing therapy administration may be a driver of ad-
herence. The association of both treatment adherence and positive clinical out-
come with DOT may exist in other disease indications.
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OBJECTIVES: The hospital burden and costs of pneumonia, meningitis, and septice-
mia remain high. A retrospective database analysis was conducted for years 2004–
2010 to quantify incidence, case-fatality, length of stay, and cost of hospitalization
from all-cause pneumonia, meningitis, and septicemia in Canada (excluding Quebec).
METHODS: Hospitalizations due to these conditions from 2004–2010 were identi-
fied from a national database in Canada using International Classification of Diseas-
es-10 codes. Statistics Canada provided the population at-risk data for incidence
calculations. A costing model, devised using hospitalization data from Ontario, was
used to estimate disease-specific costs. Results are reported for all age groups
combined. RESULTS: From 2004–2010, hospitalized pneumonia incidence (cases
per 1,000-persons) declined from 3.61 to 3.47, case-fatality rates declined from
12.3% to 11.6%, and average length of hospitalization increased from 9.99 to 10.54
days. Hospitalized meningitis incidence (cases per 100,000-persons) increased
non-monotonically from 4.20 to 4.67, case-fatality rates increased from 5.5% to
6.6%, and average length of hospitalization increased from 12.36 to 12.88 days.
Hospitalized septicemia incidence (cases per 100,000-persons) increased from
74.28 to 82.03, case-fatality rates remained at approximately 26%, and average
length of hospitalization increased from 14.76 to 16.68 days. From 2004–2009, av-
erage total costs (Canadian $) increased from $12,195 to $15,742 for pneumonia,
remained at approximately $19,000 for meningitis, and increased from $22,289 to
$31,019 for septicemia. Incidence patterns for the three conditions differed by age
and gender. CONCLUSIONS: The clinical and economic burden due to all-cause
hospitalized pneumonia, meningitis, and septicemia across all ages combined
have not demonstrated major reductions during the period reviewed and remain
high, particularly for pneumonia. However, the pattern varied by age group. Sub-
stantial savings in costs and hospital resources may accompany prevention of
these conditions by measures aimed at major underlying causes, such as influenza
virus and Streptococcus pneumoniae.
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OBJECTIVES: To provide an overview on the epidemiology of Staphylococcus aureus
(SA) infection in children from North America and Europe. METHODS: A literature
review was conducted using Medline and based on 4 different search strategies to
focus on a children population from birth to 18 years of age and to identify publi-
cations from the last 10 years. RESULTS: A total of 233 abstracts were retrieved,
resulting in the selection of 21 publications. Findings suggest increased incidence
rates of hospital-acquired (HA) SA infections worldwide over time. For instance in
the USA, the increase in the overall incidence of SA infection among children is
significant: from 20.8/1000 admissions in 2002 to 35.8/1000 admissions in 2007, as
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well as in the incidence of Methicillin-Resistant SA (MRSA) infection among chil-
dren: from 6.7/1000 admissions in 2002 to 21.2/1000 admissions in 2007. The most
frequent clinical manifestations of SA infections include abscess and cellulitis,
pneumonia, osteomyelitis and bacteremia. Children under the age of one year have
a substantially higher rate of SA bloodstream (SAB) infections. Mortality rate due to
SAB is up to 10% in neonates while approximately 2% among children. Rates of
MRSA infections vary by geography: highest in the USA (31.4-59.5% of HA SA infec-
tions) and Southern Europe (28-63%), lower rates in Central Europe (6-22%) and the
lowest rates in Northern Europe (1%). MRSA infections are associated with higher
rates of crude mortality than Methicillin-Sensible SA (MSSA) infection worldwide
(OR: 1.93, 95%CI 1.54-2.12 – Shorr et al 2007). CONCLUSIONS: Serious SA infection
represents a substantial and potential growing public health problem in the pedi-
atric population. Given the difficulty of developing new classes of antibiotics and
the increasing likelihood of resistance developing to all currently available antibi-
otics, a vaccine could help to prevent these infections in children and reduce as-
sociated morbidity and mortality.
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OBJECTIVES: To describe the initial decision to prescribe telbivudine and the pre-
scription patterns in outpatient clinical settings in Europe. To assess the prescrib-
er=s knowledge regarding the safety profile of telbivudine. METHODS: This obser-
vational cross sectional study examined the initial decision to prescribe
telbivudine and the prescribing patterns among 48 physicians randomly selected
in Germany, Italy and Spain. Physicians were eligible to take part in the study if
they had prescribed telbivudine in the 12 months before the survey. RESULTS:
More than 96% of the participating physicians were prescribing entecavir, telbivu-
dine and tenofovir disoproxil fumarate at the time of the survey. Physicians re-
ported a varied frequency for monitoring HBV DNA and alanine transferase (ALT)
levels after initiation of telbivudine treatment (94% monitor at least at 6 months
and 6% monthly). Drug characteristics most frequently mentioned by physicians as
the reason to initiate treatment with telbivudine were rapid viral suppression
(70%), efficacy in treatment-naïve patients (69%), favorable safety profile (49%) and
predictable clinical outcomes (41.8%). Considering the characteristics of the indi-
vidual patient at treatment initiation, the most frequent reasons to prescribe tel-
bivudine were the patient’s viral load at start of treatment (77%), age (62%) and
serum ALT level (41%). Physicians reported being aware of the requirement for
monitoring possible side effects particularly muscle related events and changes in
renal function. CONCLUSIONS: Overall, these results indicate that physicians in
the EU who prescribe telbivudine are aware of the potential benefits and risks of
telbivudine treatment and the prescription is based on the well validated manage-
ment guidelines (roadmap concept).
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OBJECTIVES: Vaccination against varicella is discussed in literature with regard to
the possible effects on the incidence of herpes zoster, as both are caused by the
varicella-zoster virus (VZV). We investigated whether temporal trends exist in the
incidence of varicella and the incidence of herpes zoster. We also conducted a
case-control study to investigate the boosting effect within families, based on our
information on household situation. METHODS: Using Dutch general practitioner
(GP) practices and pharmacies databases, longitudinal data, including free text
fields, was collected about varicella and herpes zoster from approximately 165,000
patients over 7 years. Data included date of birth, date of diagnosis, gender and
household situation. RESULTS: A seasonal trend for the incidence of varicella was
found with a peak in spring, but no temporal trend was found for the incidence of
herpes zoster. The results of the case-control study show the following: people
living within the same households as varicella patients are less likely to develop
herpes zoster within the period of / 2 months after exposure to varicella (mean
age is 22.9 years; OR is 0.4; 95% CI: 0.3-0.5). However people within the same house-
holds as varicella patients are more likely to develop herpes zoster within 2 months
to 7 years after exposure to varicella (mean age is 27.9 years; OR is 1.3; 95% CI:
1.1-1.5).CONCLUSIONS: The trend analyses show a seasonal trend in the incidence
of varicella where the incidence of herpes zoster is more or less stable over time.
The case-control study shows that people within the same household with vari-
cella patients are less likely to develop herpes zoster immediately after exposure
and more likely to develop herpes zoster later in life. As herpes zoster is positively
correlated with age this is expected.
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OBJECTIVES: Gonorrhea is the second most commonly reported bacterial STD,
most of which is diagnosed in the private sector. STD treatment guidelines suggest
retesting people with gonorrhea 3 months post treatment. The objective was to
examine the rate and predictors of re-testing within 3-6 months among privately
insured patients (15-50 years) diagnosed with gonorrhea.METHODS:A commercial
insurance database was used to extract patients with gonorrhea (ICD-9-CM codes:
98.xx) in year 2007-2009. The date of first gonorrhea diagnosis was used as the
index date. Patients were required to have health insurance  6 months before
and after the index date. We also defined the re-screening service for gonorrhea by
using the CPT codes: 87081, 87205, 87590, 87591, 87492, 87800, and 87801 within 3-6
months after the index date. Logistic regression model was used to identify factors
affecting the likelihood of gonorrhea retesting. RESULTS: Among 1016 persons
diagnosed with gonorrhea, about 48% were in the age group 15-25 years, 36% in
25-40 years, and 16% in 40-50 years. The majority were women (61.4%). Only 110/
1016 (10.8%) patients were rescreened within 3-6 months. The re-screening rates in
2007, 2008, and 2009 were 6.1%, 11.6%, and 13.7%, respectively. The re-screened
individuals were more likely to be: women but not pregnant (OR1.93, 95% CI:
1.20-3.12), pregnant women (OR4.46, 95% CI: 2.17-9.19), compared to men; age
15-25 years old (OR2.65, 95% CI1.17-6.00) and 25-40 years old (OR2.65, 95% CI:
1.15-6.09), compared to age 40-50 years old; and those diagnosed in 2008 (OR2.11,
95% CI: 1.15-3.85) and 2009 (OR2.44, 95% CI: 1.28-4.66), compared to 2007.
CONCLUSIONS: While rescreening rates are increasing among privately insured
patients diagnosed with gonorrhea, they are still very low. To improve rescreening
rate, policy makers should urgently consider policy options including rescreening
of all gonorrhea cases for effective control of the disease.
Infection – Cost Studies
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(PCV13) IN GERMANY
Jiang Y1, Gauthier A1, Annemans L2, van der Linden M3, Nicolas-Spony L4, Bresse X4
1Amaris Consulting UK, London, UK, 2Ghent University, Ghent, Belgium, 3National Reference
Centre for Streptococci, Aachen, Germany, 4Sanofi Pasteur MSD, Lyon, France
OBJECTIVES: Streptococcus pneumoniae is a leading cause of life-threatening pneu-
mococcal diseases (PDs). In Germany, PPV23 has been recommended in the elderly
(aged 60 and over) since 1998. In 2006, the pneumococcal conjugate vaccine (PCV)
was introduced in children and is expected to be launched in adults shortly. US
experience showed that PCV vaccination of children led, ten years after its intro-
duction, to a decrease in the incidence of invasive PD (IPD) caused by the PCV
serotypes and to an increase in IPD caused by the non-PCV serotypes. This study
aimed to assess the BI of vaccinating at-risk adults and the elderly (aged 60 and
over) with PPV23 and/or PCV13 in Germany. METHODS: A multi-cohort, popula-
tion-based Markov model was developed, consisting of five health states: no PD,
IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis sequelae
and death. Cohorts of individuals receiving initial vaccination, and the unvacci-
nated individuals were followed over time. All data were retrieved from published
sources. German epidemiological trends were modelled according to US data. As
vaccine effectiveness in adults against the vaccine-serotypes is not available for
PCV13, optimistic and pessimistic hypotheses were defined. The net budget impact
(NBI) was calculated for the 2012-2016 period. RESULTS: Vaccinating German at-
risk adults and the elderly with PCV13 at current vaccine uptake resulted in an
undiscounted NBI of €239 million in the base case, which is 22% higher than vaccinat-
ing with PPV23. No scenario was found in favour of PCV13. Results were sensitive to
vaccination uptake, vaccine prices, vaccine effectiveness and epidemiological trends
assumptions. CONCLUSIONS: Using a population-based approach, our model was
designed to simulate the progression of PDs in a changing environment in terms of
demographics, epidemiology and available vaccines. According to this analysis,
PCV13 is likely to result in a significant impact on the healthcare budgets.
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OBJECTIVES: To estimate the impact of tenofovir reimbursement in treatment of
adults with chronic hepatitis B in Poland.METHODS:Analysis was performed from
the public payer perspective in 5-year time horizon. Target population was defined
as adults with chronic hepatitis B who are eligible for antiviral treatment. Size of
the target population was estimated on the basis of Polish sales data obtained from
IMS, including the sale of nucleoside analogues in the period January 2007-March
2010. In the analysis following cost categories were included: drugs (tenofovir,
entecavir, adefovir, lamivudine), monitoring, hospitalizations and complications
of hepatitis-B (cirrhosis, hepatocellular carcinoma). Reimbursement assumption
was that tenofovir will be financed in heath therapeutic program on the basis of
financing principles of entecavir and adefovir. It was assumed that tenofovir will be
initial (first choice) therapy in population of patients who are eligible to tenofovir,
entecavir or adefovir therapy and that in case of reimbursement tenofovir will be
replacing entecavir and adefovir. RESULTS: The size of target population will be
circa 4100 people in 2011 and increases to circa 6200 people in 2015. Forecast pop-
ulation of patients using tenofovir is ca 1500 patients in 2011 and will grow to ca
3200 patients in 2015. In current scenario (lack of tenofovir reimbursement) expen-
ditures on antiviral drugs in target population will be ca 76,000,000 PLN in 2011 and
will steadily increase to ca 120,000,000 PLN in 2015. Total expenditures in the target
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